| 000 | 01831 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250517195750.0 | ||
| 264 | 0 | _c20190924 | |
| 008 | 201909s 0 0 eng d | ||
| 022 | _a1532-6535 | ||
| 024 | 7 |
_a10.1002/cpt.1037 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSuri, Ajit | |
| 245 | 0 | 0 |
_aPopulation PK and Exposure-Response Relationships for the Antibody-Drug Conjugate Brentuximab Vedotin in CTCL Patients in the Phase III ALCANZA Study. _h[electronic resource] |
| 260 |
_bClinical pharmacology and therapeutics _c11 2018 |
||
| 300 |
_a989-999 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Immunological _xadministration & dosage |
| 650 | 0 | 4 | _aBrentuximab Vedotin |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 | _aClinical Trials, Phase III as Topic |
| 650 | 0 | 4 | _aComputer Simulation |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aDrug Dosage Calculations |
| 650 | 0 | 4 | _aDrug Monitoring |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoconjugates _xadministration & dosage |
| 650 | 0 | 4 |
_aLymphoma, T-Cell, Cutaneous _xblood |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aModels, Biological |
| 650 | 0 | 4 | _aProgression-Free Survival |
| 650 | 0 | 4 | _aRisk Assessment |
| 650 | 0 | 4 |
_aSkin Neoplasms _xblood |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aMould, Diane R | |
| 700 | 1 | _aLiu, Yi | |
| 700 | 1 | _aJang, Graham | |
| 700 | 1 | _aVenkatakrishnan, Karthik | |
| 773 | 0 |
_tClinical pharmacology and therapeutics _gvol. 104 _gno. 5 _gp. 989-999 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/cpt.1037 _zAvailable from publisher's website |
| 999 |
_c28021031 _d28021031 |
||